Industry Liaison Forum

The IAS-ILF is a mechanism to inform and support collaboration and partnership between industry, the IAS and other stakeholders. It performs this broad task by providing opportunities for industry to understand the IAS’s values, interests and priorities, and vice versa, seeking common ground to enhance the impact of the global response to HIV and related comorbidities.

The IAS-ILF aims to promote constructive interactions among all stakeholders, including industry, and convene experts from industry and non-industry organizations to discuss topics relevant to IAS Member Priorities. The IAS-ILF is designed to take advantage of the IAS’s key strengths: its well-respected convening power; its acknowledged independence towards industry and other key partners and stakeholders; and its diverse working groups composed of some of the world’s top thought leaders and scientific experts in a wide array of fields.

Latest Publication

IAS-ILF/CIPHER Thematic Roundtable on Paediatric HIV

Removing barriers and seizing opportunities in paediatric HIV

Following the success of the IAS-ILF Industry Roundtable on Paediatric Antiretrovirals, held in Geneva, Switzerland, in November 2013, the IAS-ILF and the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) teamed up to organize a follow-up roundtable on paediatric HIV. This closed meeting was held in conjunction with AIDS 2014 (20-25 July 2014, Melbourne, Australia). It was aimed at bringing cohorts (through the CIPHER Cohort Collaboration) and industry together for an informal discussion and knowledge sharing between stakeholders, hoping to extend collaboration between cohort investigators and industry. Normative and regulatory agencies were also represented. The IAS-ILF/CIPHER Thematic Roundtable on Paediatric HIV was co-chaired by Lynne Mofenson (US National Institutes of Health, USA) and Shaffiq Essajee (Clinton Health Access Initiative, USA). This thematic roundtable highlighted the common goal shared by stakeholders: contributing to the development and distribution of better antiretroviral regimens to more infants, children and adolescents. Challenges and opportunities were highlighted during the discussion, as well as potential avenues for follow up through the CIPHER Cohort Collaboration.

The meeting agenda, report and presentations are available for download here.

IAS-ILF Corporate Partners

A list of previous sponsoring industry partners is available here.




11 February 2015
‘The Corporate Reputation of Pharma in 2014 —the Patient Perspective’, and how the corporate reputation of pharma companies has changed over the past four years

6 February 2015
The Female Health Company (FHC) joins the IAS-ILF Corporate Partnership Programme as an IAS-ILF Bronze Partner

3 February 2015
Alere joins the IAS-ILF Corporate Partnership Programme as an IAS-ILF Silver Partner

20 January 2015
UN chief appoints new Special Envoy in move to end Tuberculosis

9 January 2015
FDA approves Roche's blood screening assay for simultaneous detection and identification of three major viral targets

7 January 2015
Manuel Gonçalves, Vice President and Head of External Affairs and Communication at ViiV Healthcare, becomes the IAS-ILF Industry Co-Chair, in replacement to Scott Purdon.

19 December 2014
AbbVie receives U.S. FDA approval of VIEKIRA PAK (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) for the treatment of chronic genotype 1 hepatitis C

15 December 2014
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally

15 December 2014
CLIA-waived HIV test enables earlier detection

12 December 2014
The IAS announces Amsterdam as site of the International AIDS Conference in July 2018

Articles from previous years are available here